Clinical Trial Results: Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Revumenib in colorectal cancer and other solid tumors has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Solid Tumors

Drugs mentioned

• Revumenib (revumenib)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Colorectal Cancer, Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-07-06